Australian study fills evidence gap for MTX as steroid-sparing agent in PMR

The case for prescribing methotrexate (MTX) as a steroid-sparing agent in established Polymyalgia Rheumatica (PMR) has been bolstered with new Australian evidence showing it improves inflammatory markers and reduces prednisolone dose in some patients who were unable to wean corticosteroids. A retrospective observational study looked at 70 patients attending two outpatient clinics in South Australia. ...

Already a member?

Login to keep reading.

© 2021 the limbic